Publications: 2000-2008: A Nicolini

  1. Nicolini A,Carpi A. Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumor Biol 2000; 21: 235-248.

  2. Nicolini A, Carpi A, Ferrari P, Anselmi L, Spinelli C, Conte M, Miccoli P. The role of tumour markers in improving the accuracy of conventional chest x-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br J Cancer 2000; 83: 1412-1417.

  3. Nicolini A, Carpi A, Ferrari P, Tartarelli G, Anselmi L, Metelli MR, Gorini I, Spinelli C, Miccoli P, Giardino R. Long-term monitoring of cell-mediated immunity in disease-free breast cancer patients. a preliminary retrospective study. Biomed Pharmacother 2002; 56: 339-344.

  4. Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P. “Tumour marker guided” salvage treatment prolongs survival of breast cancer patients: final report of a 7 year study. Biomed Pharmacother 2003; 57: 452-459.

  5. Nicolini A, Carpi A. Advanced breast cancer: an update and controversies on diagnosis and therapy. Biomed Pharmacother 2003; 57: 439-446.

  6. Nicolini A, Carpi A, Ferrari P, Pieri L. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol 2003; 24(6): 275-80.

  7. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004; 58(1): 24-38.

  8. Gasbarri A, Marchetti C, Iervasi G, Bottoni A, Nicolini A, Bartolazzi A, Carpi A. From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules. Biomed Pharmacother 2004; 58(6-7): 356-9.

  9. Capirci C, Rubello D, Chierichetti F, Crepaldi G, Carpi A, Nicolini A, Mandoliti G, Polico C. Restaging after adjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother 2004; 58(8): 451-457.

  10. Nicolini A, Mancini PA, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, Carpi A, Giardino R.Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 2004; 58(8): 447-450.

  11. Nicolini A, Campani D, Miccoli P, Spinelli C, Carpi A, Menicagli M, Ferrari P, Gadducci G, Rossi G, Fini M, Giavaresi G, Bonazzi V, Giardino R. Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: a case-control study. Int J Biol Markers 2004; 4(19): 275-281.

  12.  Nicolini A, Carpi A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed Pharmacother 2005; 59: 253-263.

  13. Nicolini A, Carpi A, Rossi G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunological parameters. J Immunother 2005; 28(3): 276-279.

  14. Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci 2006; 11: 1818-1843.

  15. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006; 17: 325-337.

  16. Carpi A, Mechanick JI, Nicolini A, Rubello D, Iervasi G, Bonazzi V, Giardino R. Thyroid nodule evaluation: what have we really learned from recent clinical guidelines? Biomed Pharmacother 2006; 60(8): 393-395.

  17. Carpi A, Naccarato AG, Iervasi G, Nicolini A, Bevilacqua G, Viacava P, Collecchi P, Lavra L, Marchetti C, Sciacchitano S, Bartolazzi A. Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer 2006; 95(2): 204-9.

  18. Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S, Conte M, Fini M, Giavaresi G, Berti P, Miccoli P. Metastatic breast cancer: an updating. Biomed Pharmacother 2006; 60: 548-556.

  19. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, Conte M, Berti P, Miccoli P. Intensive post-operative follow-up of breast cancer patients with tumourmarkers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006;6: 269.

  20. Nicolini A, Carpi A, Rossi G. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. Cancer Lett 2007; 251(2): 330-8.

  21. Balzan S, Nicolini G, Forini F, Boni G, Del Carratore R, Nicolini A, Carpi A, Iervasi G. Presence of a functional TSH receptor on human erythrocytes. Biomed Pharmacother 2007; 61(8): 463-467.

  22. Carpi A, Nicolini A, Marchetti C, Iervasi G, Antonelli A, Carpi F. Percutaneous large-needle aspiration biopsy histology of palpable thyroid nodules: technical and diagnostic performance. Histopathology 2007; 51(2): 249-57.

  23. Nicolini A, Carpi A, Ferrari P, Rossi G. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: A retrospective longitudinal study. Cancer Lett 2008 Jan 30; [Epub ahead of print].

  24. Nicolini A, Ferrari P, Cavazzana A, Carpi A, Berti P, Miccoli P. Conventional and new emerging prognostic factors in breast cancer: an update. Biomarkers Med 2007; 1(4): 525-540.

  25. Carpi A, Di Coscio G, Iervasi G, Antonelli A, Mechanick J, Sciacchitano S, Nicolini A. Thyroid fine needle aspiration: How to improve clinicians' confidence andperformance with the technique.Cancer Lett 2008; 264(2): 163-71. Epub 2008 Apr 1.